Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Adempas - withdrawal of application for variation to marketing authorisation

Adempas - withdrawal of application for variation to marketing authorisation

Application withdrawn

The application for a change to this medicine's authorisation has been withdrawn.

riociguat
Post-authorisationHuman

Page contents

  • Overview
  • Key facts
  • Documents
  • Related information on withdrawals
  • News on Adempas
  • More information on Adempas

Overview

On 11 August 2016, Bayer Pharma AG officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a change to the marketing authorisation for Adempas, in the treatment of pulmonary arterial hypertension.

Adempas is a medicine that contains the active substance riociguat. It is available as tablets (0.5, 1, 1.5, 2 and 2.5 mg).

Adempas has been authorised since March 2014. It is already used to increase the ability to carry out physical activity in adults with the following forms of pulmonary hypertension (high blood pressure in the blood vessels of the lungs):

  • Chronic thromboembolic pulmonary hypertension (CTEPH, where the blood vessels in the lungs are blocked or narrowed by blood clots). Adempas is used to treat patients with CTEPH who cannot be operated on, or in whom CTEPH remains or returns after surgery.
  • Pulmonary arterial hypertension (PAH, where the walls of the blood vessels of the lungs are thickened and the vessels become narrowed). Adempas can be used on its own or in combination with other medicines for PAH called 'endothelin receptor antagonists'.

Adempas is used in patients with functional class II to III CTEPH or PAH. The 'class' reflects the severity of the disease: 'class II' involves slight limitation of physical activity while 'class III' involves marked limitation of physical activity.

For PAH, Adempas was found to be effective in patients with idiopathic (of unknown cause) or inherited PAH or PAH caused by connective tissue disease.

Adempas was also expected to be used specifically for the treatment of adults with PAH associated with congenital heart disease (heart disease present at birth).

Adempas was designated an 'orphan medicine' (a medicine to be used in rare diseases) on 20 December 2007 for the treatment of PAH including CTEPH. This orphan designation covers PAH associated with congenital heart disease (PAH-CHD).

In PAH-CHD, Adempas is expected to work in the same way as it does in its existing indications. The active substance in Adempas, riociguat, stimulates an enzyme called 'soluble guanylate cyclase' in the blood vessels of the lungs, which causes the blood vessels to relax and widen. This helps to lower the blood pressure in the lungs and improve symptoms of PAH.

The company did not conduct any new studies. It provided an analysis of results in patients with PAH-CHD taken from the main studies in PAH patients which compared Adempas with placebo (a dummy treatment). About 8% of patients in the main studies had PAH-CHD. The main measure of effectiveness was the increase in the distance patients could walk in 6 minutes (a way of measuring exercise capacity).

The application was withdrawn after the CHMP had evaluated the initial documentation provided by the company and formulated a list of questions to be answered. The company had not yet responded to the questions at the time of the withdrawal.

Based on the review of the data, at the time of the withdrawal, the CHMP had some concerns. However, the CHMP thought that the company could have addressed these concerns and was of the provisional opinion that Adempas could have been approved for the treatment of PAH-CHD.

The CHMP's main concern was that because the main study had not been set up to investigate Adempas specifically in patients with PAH-CHD, the results were not suitable for determining the effectiveness of the medicine in this subgroup of patients. The CHMP was also concerned that few patients with PAH-CHD were investigated and that the analysis of side effects in PAH-CHD patients was not sufficiently robust.

Therefore, at the time of the withdrawal, the CHMP was of the opinion that the company had not fully addressed their concerns and the benefit and risks of Adempas in the specific treatment of PAH-CHD had not been demonstrated satisfactorily.

In its letter notifying the Agency of the withdrawal of application, the company stated that the withdrawal is based on the revised product development strategy for the product.

The withdrawal letter is available below.

The company informed the CHMP that this withdrawal has no impact on patients participating in ongoing clinical trials or compassionate use programmes with Adempas.

If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.

There are no consequences on the use of Adempas in its authorised indications.

Questions and answers on the withdrawal of the application for a change to the marketing authorisation for Adempas (riociguat)

Reference Number: EMA/560099/2016

English (EN) (86.37 KB - PDF)

First published: 16/09/2016Last updated: 16/09/2016
View

Key facts

Name of medicine
Adempas
EMA product number
EMEA/H/C/002737
Active substance
riociguat
International non-proprietary name (INN) or common name
riociguat
Therapeutic area (MeSH)
Hypertension, Pulmonary
Anatomical therapeutical chemical (ATC) code
C02KX05
Marketing authorisation holder
Bayer AG
Date of issue of marketing authorisation valid throughout the European Union
27/03/2014
Date of withdrawal
11/08/2016

Documents

Withdrawal letter Adempas

English (EN) (19.87 KB - PDF)

First published: 16/09/2016Last updated: 16/09/2016
View

Related information on withdrawals

The question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the application at the time of the withdrawal, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 90').

News on Adempas

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025
25/04/2025
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023
26/04/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021
17/09/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2016 (corrected)
21/09/2016
Adempas not for use in patients with pulmonary hypertension caused by idiopathic interstitial pneumonia
24/06/2016
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 January 2014
24/01/2014

More information on Adempas

  • Adempas
  • Clinical data (variation II/0011)

 

This page was last updated on 16/09/2016

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union